The bacterial hyaluronan lyases (Hyal) 
Introduction
The glycosaminoglycan hyaluronan (hyaluronic acid, HA) was first isolated from the vitreous humour of bovine eyes (Meyer, K. and Palmer, J.W. 1934) and is a major component of the extracellular matrix (ECM) of animal tissues. This strictly linear polymer consists of repeating disaccharide units of (β,1-4)-D-glucuronic acid-(β,1-3)-N-acetyl-D-glucosamine. It has been identified in the capsule of some bacteria, and in essentially all vertebrates where it is present in significant quantities in skin (dermis and epidermis), brain, and the central nervous system (Laurent, T. and Fraser, J. 1992) . HA is degraded by hyaluronidases, a class of enzymes with two main families, the eukaryotic hyaluronoglucosaminidases (EC 3.2.1.35) and the prokaryotic hyaluronan lyases (EC 4.2.2.1) (Coutinho, P.M. and Henrissat, B. 1999, Kreil, G. 1995) .
The best characterized of the bacterial enzymes are Streptococcus pneumoniae and Streptococcus agalactiae hyaluronan lyases Chantalat, L. 2000) . Both enzymes degrade HA at the β-1,4-glycosidic linkage between D-glucuronic acid and N-acetyl-D-glucosamine. The product of this elimination reaction is the unsaturated disaccharide 2-acetamido-2-deoxy-3-O-(β-D-gluco-4-enepyranosyluronic acid)-D-glucose (Kreil, G. 1995, Linker, A. and Meyer, K. 1954) . The three-dimensional (3D) structures of S.
pneumoniae and S. agalactiae strain 3502 hyaluronan lyases were elucidated by X-ray analyses in the native as well as in the complex forms with both substrates and products , Jedrzejas, M.J. and Chantalat, L. 2000 , Li, S., Kelly, S., et al. 2000 . The structures of both enzymes are similar and contain distinct domains with the largest domain being catalytic. The active site of the S. pneumoniae enzyme (SpnHyal), schematically depicted in Figure 1 , is located in a long cleft of the catalytic domain that binds the substrate and consists of four main parts: a positive patch, a catalytic triad (His399, Tyr408 and Phe343) responsible for correct positioning of the substrate chains for catalysis, and a negative patch implicated in the release of the product (Glu388, Asp398, and Thr400) (Li, S., Kelly, S., et al. 2000) . Successive structural , Li, S., Kelly, S., et al. 2000 , Ponnuraj, K. and Jedrzejas, M.J. 2000 and mutagenesis studies , Li, S., Kelly, S., et al. 2000 , Nukui, M., Taylor, K.B., et al. 2003 have enabled the formulation of a firmly supported catalytic mechanism, as reported (Jedrzejas, M.J. 2001 . This mechanism is based on acid/base type β-elimination with His399 serving as base, and Tyr408 as acid (Fig. 1 ).
The Hyal enzymes identified in two S. agalactiae strains, 4755 (SagHyal 4755 ) and 3502
(SagHyal 3502 ), have nearly identical sequences (98% identity) (Ponnuraj, K. and Jedrzejas, M.J. 2000) , and show 53% identity with the S. pneumoniae enzyme. In contrast to the structure of SpnHyal, a fully-active two-domain truncated version (Li, S., Kelly, S., et al. 2000) , the SagHyal 3502 structure reveals an additional third domain at the N-terminus which is presumed to act as a spacer . Bioinformatic studies identified a further domain at the extreme N-terminus in all bacterial Hyal enzymes, including S. pneumoniae and S.
agalactiae, that is responsible for substrate binding but not for catalysis .
Unsaturated disaccharides are the only degradation products of exhaustive digestion of HA by Hyals. These disaccharides might be utilized by bacteria as an additional carbon source (Hynes, W. and Walton, S. 2000) . (Hynes, W. and Walton, S. 2000) . Streptococcal Hyal is therefore a significant virulence factor. Human infection by such pathogens is one of the major causes of meningitis, septicemia, as well as many other serious diseases that lead to neonatal mortality (Dillon, H.C., Jr., Khare, S., et al. 1987, Hynes, W. and Walton, S. 2000) . To study the precise role of HA and Hyals in the course of bacterial infection and spread, the design and development of inhibitors was undertaken by our laboratories.
For bacterial Hyals, L-ascorbic acid (Vc, 1, Fig. 2 ) was described as a competitive inhibitor with an IC 50 value of ~6 mM . Furthermore, various unsaturated fatty acids have been reported to inhibit S. dysgalactiae Hyal, with IC 50 values ranging from 1-172 µM (Suzuki, K., Terasaki, Y., et al. 2002) . The structural basis of the SpnHyal-Vc interaction was elucidated by means of X-ray crystallography . Vc binds in the active site of the enzyme, and among the different interactions, the importance of hydrophobic contacts with Trp292 and Tyr408 was evident. Based on the hypothesis that Vc derivatives with increased hydrophobicity would be more potent, L-ascorbic acid-6-hexadecanoate (Vc palmitoate, Vcpal, 2) (Fig. 2) , a highly effective antioxidant (Klein, E. and Weber, N. 2001 ) and glutathione-S-transferase inhibitor (Mitra, A., Govindwar, S., et al. 1992) , was investigated (Botzki, A., Rigden, D.J., et al. 2004 ). The X-ray structure of the SpnHyal-Vcpal complex (Protein Data Bank (PDB) (Berman, H.M., Westbrook, J., et al. 2000) code 1w3y) (Botzki, A., Rigden, D.J., et al. 2004 ), determined at 1.65 Å resolution, confirmed the hypothesis that additional hydrophobic interactions with Phe343, His399, and Thr400 in the active site lead to increased inhibition.
Based on these studies of bacterial Hyals inhibition by Vc and Vcpal, and the discovery that SagHyal is inhibited by, e.g., 1,3-diacetylbenzimidazole-2-thione (3, Fig. 2 ), a new inhibitor 6 was designed, 1-decyl-2-(4-sulfamoyloxyphenyl)-1H-indol-6-yl sulfamate (4, Fig. 2 ) (Walter, G., Liebl, R., et al. 2004 ). In the current study, the X-ray structure of a complex of SpnHyal with this new inhibitor, compound 4, is presented, and its binding mode compared with that of a hexasaccharide HA substrate and Vcpal. In addition, the newly identified interaction pattern of compound 4 was used to predict N-substituted benzoxazole-2-thiones as additional novel Hyal inhibitors. The initial results on structure-activity relationships (SAR) in this new series support the binding mode derived from the crystallized complexes, and provide a basis for further optimization of the molecular structures of these compounds with respect to their selectivity, potency and pharmacokinetic properties.
Results and Discussion

Initial design of inhibitors
Recent structure-based design approaches using the program LUDI (Böhm, H.J. 1992 ) for docking of molecules from databases into a SagHyal 4755 model led to the prediction of numerous potential inhibitors (Botzki, A., Salmen, S., et al. 2005) . 19 compounds were synthesized, from which 13 proved to be active at SagHyal 4755 (Botzki, A., Salmen, S., et al. 2005) . 1,3-diacetylbenzimidazole-2-thione (3, Fig. 2 ) was the most potent inhibitor (IC 50 value of 5 µM at pH 7.4). Another hit from these investigations, indole-2-carboxylic acid, was active only at concentrations above 1 mM, but initiated the rational design of a series of inhibitors based on the 2-phenylindole scaffold (Salmen, S. 2003 , Walter, G., Liebl, R., et al. 2004 . The hypothesis that hydrophobic chains at the indole nitrogen may mimic the hexadecyl moiety of Vcpal (2, Fig. 2) was proposed and later confirmed. Furthermore, the most active compound of the 2-phenylindole 7 series, 1-decyl-2-(4-sulfamoyloxyphenyl)-1H-indol-6-yl sulfamate (4, Fig. 2 ) was crystallized in complex with SpnHyal.
Structure of the S. pneumoniae Hyal -phenylindole inhibitor complex
The overall protein structure of the SpnHyal-phenylindole inhibitor complex (Table I) (Fig. 3) . The aliphatic tail fits into a surface crevice lined mainly by hydrophobic residues -Met579, Trp291, Phe343 -but also by Arg336, Glu388 and His399. The lipophilic potential mapped on the surface of the binding site depicts a continuous hydrophobic region extending from Trp292 outwards to Phe343 which aligns with the indole ring and nearly the complete decyl chain (Fig. 4B ).
The 6-sulfamoyloxy group forms a network of hydrogen bonds with protein and water.
The interactions associated with binding mode 1 ( 
Comparison of the binding modes of the phenylindole and Vcpal
Apart from the alkyl chains, the phenylindole 4 and Vcpal are prima facie structurally dissimilar (Fig. 2) . Nevertheless, their bound conformations and the binding modes are similar to some extent and are therefore compared in some detail. X-ray crystallography of the co-crystallized
SpnHyal-Vcpal complex resulted in the PDB structure 1w3y (Botzki, A., Rigden, D.J., et al. 2004) . Figure 5B 
Inhibitory activity on hyaluronan lyases
The inhibitory effects of Vc (1), Vcpal (2) and the phenylindole inhibitor 4 were measured at pH 5.0 utilizing two Hyal enzymes, SagHyal from strain 4755 and SpnHyal. Concentrations for 50% inhibition (IC 50 ) are given in Table II 
Structure-based design of benzoxazole-2-thiones as hyaluronan lyase inhibitors
The 
Materials and methods
Materials
Hyaluronan (hyaluronic acid) from S. zooepidemicus was purchased from Aqua Biochem (Dessau, Germany). Bovine serum albumin (BSA) was obtained from Serva (Heidelberg, Germany). All other chemicals were of analytical grade and were obtained either from Merck (Darmstadt, Germany), from Fisher Scientific (Pittsburgh, PA, USA) or Sigma Chemical (St.
Louis, MO, USA). 16 was produced as previously described ). The enzyme was concentrated to 5 mg/ml in 10 mM Tris-HCl buffer, 150 mM NaCl, 1 mM dithiothreitol (DTT) (pH 7.4) using centrifugal spin devices with a 50 kDa molecular weight cutoff (Millipore, Billerica, USA). This preparation was used for inhibition studies and for the production of crystals of complex with inhibitor. Enzyme concentration was determined photometrically at 280 nm using a calculated molar absorption coefficient of 127,090 L·mol -1 ·cm -1 (Jedrzejas, M.J., Chantalat, L., et al. 1998) according to Pace et al. (Pace, C.N., Vajdos, F., et al. 1995) . Lascorbic acid-6-hexadecanoate was obtained as described (Botzki, A., Rigden, D.J., et al. 2004 ).
Enzymes and inhibitor preparations
1-decyl-2-(4-sulfamoyloxyphenyl)-1H-indol-6-yl sulfamate (4) (Walter, G., Liebl, R., et al. 2004 ) and the benzoxazole-2-thiones 5a -5c were synthesized in our laboratory as described (Braun, S. 2005) .
Determination of inhibitory activity on hyaluronan lyases
The inhibitory effects of the compounds on the Hyals from S. pneumoniae and S. agalactiae strain 4755 were measured using a turbidimetric assay (Di Ferrante, N. 1956 ). After incubation of the assay mixture for 30 min at 37 °C, 720 µL of a 2.5% (m/v) cetyltrimethylammonium bromide solution (2.5 g CTAB dissolved in 100 mL 0.5 M sodium hydroxide solution, pH 12.5) were added to precipitate the residual high molecular weight substrate and to stop the enzyme reaction. This mixture was again incubated at 25 °C for 20 min, and the turbidity of each sample was determined at 600 nm with an Uvikon 930 UV spectrophotometer (Kontron, Eching, Germany). Experiments were performed in quadruplicate.
The turbidity of the sample without inhibitor was taken as reference for 100% enzyme activity, whereas the turbidity of the sample without enzyme (30 µL BSA) was taken as reference for 0%
enzyme activity. The activities were plotted against the logarithm of the inhibitor concentration, and IC 50 values were calculated by curve fitting of experimental data with Sigma Plot 8.0 (SPSS Inc., Chicago, USA).
Crystallization of the complex
The hanging drop vapor diffusion (McPherson, A. 1999) using Linbro culture plates (Hampton Research, Aliso Viecho, USA) at room temperature was used to grow the crystals of the enzymeinhibitor complex. Equal volumes of protein, reservoir solution (1µL each) and various amounts of inhibitor solutions (0.1, 0.5, and 1.0 µL) were mixed and equilibrated against 1 mL of the reservoir solution which contained 60-65% saturated ammonium sulfate, 0.2 M NaCl, 2%
dioxane, and 0.1 M sodium citrate buffer (pH 6.0) as reported for the native enzyme crystallization ).
X-ray diffraction
The crystals of the enzyme-inhibitor complex were cryo-protected using 30% xylitol (w/v), 3.5 were analyzed, indexed, integrated, and scaled using the HKL2000 software package (Otwinowski, Z. and Minor, W. 1997) . The resultant crystals were isomorphous to the native S.
pneumoniae hyaluronan lyase crystals .
Structure solution and refinement
The structure was solved by rigid body refinement in Crystallography & NMR System (CNS) (Brunger, A.T., Adams, P.D., et al. 1998 ) using the crystal structure of S. pneumoniae Hyal in complex with Vcpal (Botzki, A., Rigden, D.J., et al. 2004 ) as a search model. The iterative approach proceeded with alternating cycles of computational refinement with CNS (Brunger, A.T., Adams, P.D., et al. 1998 ) and manual rebuilding using O (Jones, T.A., Zou, J.Y., et al. 1991) . No intensity or sigma-based cut-offs were applied to the data. SigmaA-weighted map coefficients (Read, R.J. 1986 ) were used throughout. The R free value (Brunger, A.T. 1992) , calculated for a test set of 5% of reflections, was used to monitor the progress of refinement.
Difference density at the active site was apparent even in initial maps. The aliphatic portion of the inhibitor was relatively easily placed but different orientations of the remainder of the inhibitor were required. The possibilities were assessed using the quality of electron density maps, B-factors and the R free value as criteria. Sulfate and xylitol molecules, deriving from the crystallization and cryo-cooling solutions, respectively, were modeled into suitably shaped regions of electron density. Final statistics for the model are shown in Table I . Programs of the CCP4 package (Collaborative Computational Project, N. 1994) were used for manipulations and structural super-positions made with LSQMAN (Kleywegt, G.J. 1999) . PYMOL was used to generate illustrations (DeLano, W.L. 2003).
Molecular models of S. pneumoniae hyaluronan lyase in complex with ligands
Modeling approaches were performed using the BIOPOLYMER module of the software package Hydrophobic regions are colored in brown, polar regions in green and green-blue. The 4-sulfamoyloxy substituent is exposed to the solvent. 
